On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...